4//SEC Filing
Dupont Jakob 4
Accession 0001209191-23-047446
CIK 0001814140other
Filed
Aug 24, 8:00 PM ET
Accepted
Aug 25, 7:29 PM ET
Size
11.5 KB
Accession
0001209191-23-047446
Insider Transaction Report
Form 4
Apexigen, Inc.APGN
Dupont Jakob
Director
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2023-08-23−34,084→ 0 totalExercise: $4.59Exp: 2030-09-01→ Common Stock (34,084 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-08-23−20,489→ 0 totalExercise: $4.59Exp: 2031-02-12→ Common Stock (20,489 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-08-23−100,000→ 0 totalExercise: $2.65Exp: 2032-09-29→ Common Stock (100,000 underlying)
Footnotes (4)
- [F1]The shares subject to the option vest in 48 equal monthly installments beginning on September 10, 2020. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $26.61 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.
- [F2]This exercise price was reported incorrectly as $4.49 in a Form 3/A filed on August 24, 2023.
- [F3]The shares subject to the option vest upon the achievement of certain performance metrics. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 3,534 shares of Pyxis common stock at an exercise price of $26.61 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.
- [F4]The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.
Documents
Issuer
Apexigen, Inc.
CIK 0001814140
Entity typeother
Related Parties
1- filerCIK 0001553335
Filing Metadata
- Form type
- 4
- Filed
- Aug 24, 8:00 PM ET
- Accepted
- Aug 25, 7:29 PM ET
- Size
- 11.5 KB